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Introduction
Tobacco smoking results in an estimated 480,000 deaths and
$300 billion in healthcare costs in the U.S., annually.1 Smoking
kills more people than alcohol, AIDS, car accidents, illegal drugs,
and homicide/suicide combined. More than 16 million people
currently suffer smoking related illness. Smoking is the leading
cause of both coronary heart disease and cancer, which together
comprise the two leading causes of mortality. Though the past 50
years has brought about significant public health improvements in
tobacco control, the prevalence of smoking has declined only
incrementally in recent years, with current national prevalence at
17%.2 There are clear needs to improve smoking cessation at the
individual level and, perhaps more importantly, at the population
level.
The basic principles of promoting smoking cessation on a
population-wide basis are rooted in the following formula3:
Impact = PQA x PQuit Method x Psuccess/method
where PQA is the probability of making a quit attempt (QA), PQuit
Method is the probability of using a specific quit method for that
attempt, and Psuccess/method is the probability of success for that
method. The goal of any population-based smoking cessation
effort is to increase the probabilities of making a quit attempt,
using evidence-based methods, and improving upon those
methods. Most clinical efforts focus on the latter; i.e., developing
new and improved cessation techniques (behavioral or
pharmacotherapy). There are a number of evidence-based
treatment options for smoking cessation. USPHS clinical
practice guidelines4 and other meta-analyses5-7 provide systematic
reviews of empirically supported methods for treating tobacco
dependence. Chief among these recommendations are that 1) all
tobacco users should be offered brief advice to assist them with
quitting, and 2) unless medically contraindicated, all smokers
should be offered pharmacotherapy. Consistent with the latter, the
most widely used medication is nicotine replacement therapy
(NRT): patch, gum, lozenge, nasal spray, and inhaler. Among
these options, only patch, gum, and lozenge are available over the
counter, and thus offer greatest potential for translational
effectiveness. NRT medications work to alleviate withdrawal
and craving that are so common when quitting,8,9 thereby
increasing the likelihood of long-term success. All are safe, and,
as a general rule, will double one’s probability of achieving
abstinence.7 Other cessation medications exist (varenicline and
bupropion), each with a substantial evidence base,10-14 but are
prescription based and offer reduced availability and access.
Another approach, just as reasonable, is to focus on the former
inputs in the above equation; i.e., getting more smokers to try to
quit, and moving them to use the best known methods. This has
been a greater challenge. The incidence rate of quit attempts (i.e.,
percent of smokers who make a quit attempt each year) has not
changed much in over a decade.15 Among those who do make a
quit attempt, use of pharmacotherapy is low.16-18 Most smokers
attempt to quit on their own, which is the least successful way to
quit.4,19 In fact, epidemiological data as applied to the above
formula show that unassisted quitting (i.e., “cold turkey”) has the

largest population impact overall – not because it so efficacious
(it has a very low Psuccess/method), but because it is so predominant
(very high PQuit Method). Tobacco control efforts should shift this
balance, focusing on an increase of quit attempts using evidencebased treatments.
There are a number of well-established methods to induce
quitting among smokers, including both policy-based (e.g.,
taxation, smokefree legislation) and clinical. Examples of the
latter include physician advice and motivational interviewing,
both of which have substantial evidentiary basis.20-22 However,
such strategies often rely on persuasive messaging, eliciting
reasons for quitting and obstacles to change. While effective for
some, many clinicians and smokers can feel frustrated by verbal
techniques, and additional options are needed. Our group has
been examining concrete, behavioral, and pragmatic strategies to
promote quit attempts and use of evidence-based treatment,
particularly among those who express unwillingness to do so.
Our view of pragmatic strategies is similar to others,23-25 with an
emphasis on methods that are brief, feasible, scaleable, easily
understood (by both provider and smoker), and easily
disseminated. We believe such novel strategies are needed to
address separate elements of the equation above, with a particular
focus on increasing the both incidence of quit attempts and usage
of evidence-based treatment. Below we document a series of
studies along this theme.

Smoking Reduction
Under the premise that reduction might facilitate quit attempts,
we conducted a nationwide, randomized clinical trial (N=616) in
which we randomized smokers who did not want to quit into one
of three groups: 1) NRT-assisted reduction counseling, 2) timematched motivational advice, or 3) no treatment control.26 Our
trial was an explicit test of whether reduced smoking per se
would serve as a catalyst to cessation among smokers not wanting
to quit, not to be confused with the process of gradual quitting
among smokers with firm quit plans. Participants were recruited
through market research panels and all interventions were
administered via phone and mail. Smokers in the reduction group
were guided through a structured protocol to reduce smoking by
50%, after which they were prompted with firm advice to quit
entirely. The rationale for reduction was simple – that it would
provide concrete evidence of success and control over smoking,
however incremental, and that this would bolster confidence and
strengthen motivation to quit.
Outcomes were tracked
prospectively for six months, and results supported the main
hypothesis: more smokers in the reduction (43%; RR = 2.8; 95%
CI: 1.9 – 4.0) and motivational (51%; RR = 3.3; 95% CI: 2.3 –
4.7) conditions made a 24-hour quit attempt over 6 months than
smokers in the no treatment condition (16%) but the two active
conditions did not differ. Similarly, 18% of participants within
the reduction group (RR = 4.0; 95% CI: 2.0 – 8.1), 23% of the
motivational advice group (RR = 5.4; 95% CI: 2.7 – 10.7) and
4% of the no treatment group were abstinent (7-day point
prevalence) at six months (see Figure 1) and again the two active
treatments did not differ.26 Thus, reduction facilitated quitting
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Figure 1. Incidence of quit attempts and cessation
and was as effective as motivational advice, with both options
easily disseminable among clinicians. Subsequent literature
reviews of smoking reduction, both within our group27,28 and by
others29-32 provided further support for smoking reduction as a
behavioral strategy to induce quit behavior. While our trial
results were encouraging for smoking reduction, they were
strongly confounded by NRT use. It was unclear whether the
effect on cessation was driven by a) the behavioral act of cutting
down on cigarettes per day or b) the experiential exercise of using
medication. Some evidence within our trial suggested the latter.
We subsequently isolated this effect through a series of NRT
sampling studies described further below.

Usage, Attitudes, and Perceptions of NRT
We separately conducted two complementary studies that
documented attitudes and misperceptions of cessation
medication. The first was a qualitative study of perceptions of
NRT specifically33 and highlighted enduring misperceptions
about the rationale, development, safety, and efficacy of NRT, all
of which likely undermine usage. This study also suggested
possible racial/ethnic differences in how cessation medications
are viewed, which may in part explain particularly low rates of
medication use among African American smokers. Our second
study of attitudes towards cessation pharmacotherapy was a
phone-based cross-sectional survey of South Carolina smokers.34
Attitudes towards pharmacotherapy among current smokers
(N=697) are presented in Table 1, and show modest endorsement
of treatment in general, or cessation medications in particular,
and that such barriers may differ by race. From these studies, we
believed that greater effort was needed to educate smokers about
cessation medication (NRT in particular), and that there was no
better way to learn about it than to use it.
NRT Sampling: Study 1
Our experiences above led us to investigate whether sampling of
cessation medication, and NRT specifically, would facilitate quit
attempts and cessation among smokers not yet ready to quit.

There are several mechanisms by which sampling could promote
downstream changes in smoking behavior. One is through
improved self-efficacy. As smokers gain confidence in
controlling smoking, they may be more likely to believe that total
abstinence is possible. Second, medication sampling might
heighten motivation. Whereas abrupt quitting is often daunting,
gradual exposure to cessation, particularly when that experience
is made easier through NRT, might remove some of the perceived
barriers to quitting. Third, simply trying a medication without
any firm commitment for long-term use may dispel
misperceptions and increase familiarization, directly addressing
barriers as suggested in Table 1. Finally, sampling may increase
autonomy, promoting self-control over smoking and the process
of quitting. Collectively, these principles are wholly consistent
with self-determination theory;35,36 i.e., the rationale that smokers
will be more successful if they are invested in, knowledgeable of,
and motivated for quitting if they decide for themselves the goals,
pace, and strategies for changing tobacco use. NRT give-away
programs are common within quitlines, with demonstrated
success.37-39 However, quitlines are underutilized40 and by
definition generally reach smokers who are actively seeking out
and receptive of treatment. Our goal was to take these same
principles and apply them more broadly.
We first conducted a randomized clinical trial (N=849) testing
the concept of NRT sampling to induce cessation behavior among
smokers unmotivated to quit.41,42 Smokers were again recruited
nationally via online channels for a phone-based intervention
trial, and were assessed for six months. Treatment consisted
either of 1) NRT sampling, within the context of a practice quit
attempt (PQA), or 2) PQA alone. The PQA intervention was a
behavioral exercise, within which smokers could (or could not)
sample nicotine replacement. The PQA was designed to increase
motivation, confidence, and coping skills. The added value of
NRT samples (nicotine lozenges) was hypothesized to familiarize
smokers with NRT, promote wider acceptance of it, and
ultimately to enhance motivation and confidence even further.
Though participants were provided with a brief overview of
medication and supporting rationale, a repeated theme was on
self-determined use: to use NRT “if and how you wish.” Uptake
of NRT during the sampling period was strong: 73% of smokers
used the product, for an average of 9 days. Cessation outcomes
were very promising, with significant increases in quit attempts
and some measures of abstinence (Figure 2). Follow-up
mediational analyses43 revealed that the added influence of NRT
sampling worked largely as intended, through hypothesized
mechanisms above.
NRT Sampling: Study 2
The trial above was based on unmotivated smokers only. We
next completed a separate semi-randomized pilot trial of smokers
across three groups (N=157), testing: smokers motivated to quit,
given 2-week samples of both nicotine patch and lozenge
(Motivated/NRT), vs. unmotivated smokers, either randomized to

Table 1. Attitudes towards Cessation Medications: Current Smokers1
African American
How well do medications work to help smokers quit?
How concerned are you about medication safety?
How concerned are you that you might get addicted?
How concerned are you about cost?
How much treatment of any kind do you need to quit?
How much do you need medication to help you quit?

42%
51%
30%
55%
50%
44%

Caucasian-American

p

50%
46%
23%
60%
60%
51%

.03
.17
.03
.22
.008
.07
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Figure 2. Rates of A) any quit attempt (QA), B) 24hr quit
attempt, C) floating abstinence (7 days, no smoking, at any
point in study), and D) 7-day point prevalence (PP)
abstinence at Week 26, among smokers engaged in a practice
quit attempt (PQA), with or without NRT samples.
the
same
treatment
(Unmotivated/NRT),
or
not
(Unmotivated/NoTx).44 The rationale for combination NRT was
fourfold. First, a number of studies demonstrate their efficacy
when used singularly.4 Second, they are both over the counter,
increasing their dissemination appeal within in various
populations. Third, whereas the patch provides a steady dose of
nicotine throughout the day, the lozenge is used ad libitum and
provides acute nicotine administration. These two mechanisms
might appeal to smokers differently. Fourth, two trials45,46 and a
separate review within our group47 have shown that combined use
of patch + lozenge is superior over placebo and single NRT
products. We expected superior outcomes (higher incidence of
quit attempts and cessation) within Motivated/NRT Group, since
they expressed motivation to quit and were given tools to do so,
and we anticipated inferior outcomes within Unmotivated/NoTx
Group, since they had neither. The main focus was on the
Unmotivated/NRT Group, who shared commonality with first
(active sampling of medication) and last group (unwillingness to
quit). Rates of incidence for quit attempts through three months
were ordinal:44 62% vs. 32% vs. 16% (Figure 3), while rates of
abstinence (7-day point prevalence at final follow-up) were
generally
comparable
between
Motivated/NRT
and
Unmotivated/NRT Groups (17% vs. 15%), a 3-fold increase over
Unmotivated/NoTx Group (5%; all pairwise comparisons not
statistically significant but still clinically meaningful).44 Our
results provide further support for the concept of sampling
medication as a method to induce quitting. Results also indicate
that while initial motivation to quit enhances outcomes
(Motivated/NRT vs. Unmotivated/NRT), it is not a necessary
precursor to success (Unmotivated/NRT vs. Unmotivated/NoTx).
NRT Sampling: Study 3
The collective evidence above suggests a role for medication
sampling to promote quit attempts and abstinence among
smokers. Overall effect sizes are moderate, but when applied in a
larger context, the population impact could be large. Our third
trial is a cluster randomized trial of NRT sampling within realworld, primary care settings (N=1160; 20 clinics). The study is
inclusive of all smokers regardless of motivation to quit, which
may or may not become a potential moderator of treatment
outcome. NRT sampling is particularly well suited to any
number of medical settings, much like within a dental setting
where patients are given product samples at the end of each visit,
in that it is brief (i.e. incurs no extra demands on a busy provider
or staff) and has intuitive face validity. As throughout above,

Figure 3. Rates of 24-hr Quit Attempts and Point Prevalence
Abstinence among groups of smokers who: A) endorsed
motivation to quit and received samples of nicotine patch and
lozenge (Motivated/NRT), B) did not endorse motivation to
quit but got same treatment (Unmotivated/NRT), and c) did
not endorse motivation to quit and got no treatment
(Unmotivated/NoTx).
messaging emphasizes self-determined use: ~”as your provider,
we think these medications can help, even if you’re not ready to
quit. Try them and see for yourself.” Outcomes will be assessed
through six months, and are focused across three levels: a)
individual smoker outcomes, as defined above (also: further use
of medication, use of behavioral support including quitlines), b)
provider outcomes (e.g., satisfaction and confidence in cessation
counseling), and c) aggregate clinic outcomes (e.g., screening and
treatment of all smokers, including those not within study). The
trial is ongoing and expected end date is late 2017.

Role of Alternative Tobacco Products to Promote
Quitting
The proliferation of alternative tobacco products gives rise to
parallel research questions along this same theme: what effect
will they have on quitting? The market of potentially safer
products has vastly expanded in recent years, and though there is
wide variation within this market, most new products are noncombustible and thus offer reduced harm to the individual user.
For example, low nitrosamine smokeless tobacco (LNSLT) has
been popular in Scandinavian countries for years, where rates of
lung cancer have significantly decreased.48-50 LNSLT, also
known as snus, differs from traditional smokeless tobacco in that
it is pouched, spitless, flavored, and marketed directly to cigarette
smokers as a substitute product. As such, whether and how snus
changes smoking behavior is a compelling public health question.
Snus could conceivably help smokers quit cigarettes, or,
alternatively, it could maintain dependence, allowing them to
circumvent smoking restrictions, engage in long term dual use,
and thus undermine smoking cessation. Only a few randomized
clinical trials of snus exist,51-54 and all are cessation-focused, i.e.,
recruiting smokers wanting to quit and explicitly testing snus as a
strategy to do so. These studies generally show positive effects
on snus on cessation. However, these studies do not address the
naturalistic population impact of snus on smoking behavior, and
this remains an important gap in the literature.
We first conducted two pilot studies, both randomized tests of
smokeless tobacco55,56 which generally showed reductions in
smoking and increases in motivation to quit compared to control
groups. Next, following much of the methods of the NRT
sampling studies above, our group conducted what we believe is
the largest (N=1236), longest (1-year), and most direct
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(randomized design) study of snus among U.S. smokers.
Smokers unmotivated to quit, recruited nationwide, were
provided a six-week sample of snus vs. not, followed by periodic
assessment for an additional 12 months. Sampling of snus was
entirely self-determined. The primary outcome was incidence
and duration of quit attempts, and secondary outcomes were point
prevalence abstinence from cigarette smoking, at 6 and 12
months, smoking reduction, and associated measures of quitting;
no support from the tobacco industry was provided. The trial is
recently completed and results are forthcoming elsewhere. The
results will add to the literature on snus and will provide an
important contribution to the clinical and regulatory debate as to
how these products fit within the landscape of tobacco control.
More recently, the exponential growth of electronic (e-)
cigarettes has dramatically shifted the focus of alternative
products. Models of e-cigarettes span a wide spectrum, from
disposable cartridges to highly sophisticated tank systems
including ones that allow the user to control the amount, dose,
and power of nicotine delivery. The basic operation of any ecigarette involves the heating and vaporization of nicotine; there
is no combustion. E-cigarettes attenuate craving to varying
degree,57 but this is likely dependent upon type of e-cigarette
product. Like LNSLT, growing evidence58,59 suggests that ecigarettes are safer than conventional cigarettes, delivering
significantly reduced levels of tobacco-specific nitrosamines; i.e.,
primary class of carcinogens within tobacco. How e-cigarettes
alter behavior is unclear. Only three randomized studies exist.6062 All come from abroad, and most are cessation-driven (use of
e-cigarettes to help smokers quit) and not naturalistic. Results are
generally supportive that use of e-cigarettes might facilitate
quitting, which supports some but not all indirect (i.e., nonrandomized, cross-sectional) evidence elsewhere.63-68 Our group
is now testing e-cigarettes much like we have done for NRT and
snus sampling studies above: using randomized designs but still
focusing on naturalistic, self-determined use. One placebocontrolled crossover study is recently completed, another
prospective study is ongoing, and a larger trial is planned. In
time we believe these studies will guide understanding of the
clinical and population impact of electronic nicotine delivery
systems.

Conclusion
Many smokers remain unable or unwilling to quit. Among those
who try to quit, unaided attempts are the most common, yet least
effective strategy. Many evidence-based treatments, including
those that are the most accessible, remain under-used by smokers.
Promoting active treatment to all smokers, even if they do not
wish to quit, offers a strong opportunity to increase cessation at
the population level. Increasing both the incidence of quit
attempts and the use of evidence-based treatment for those
attempts offers strong potential to move smokers away from
unproven (unassisted) ways of quitting and thus offers an
opportunity to dramatically increase the impact of smoking
cessation. Allowing smokers to sample cessation medication on
their own terms increases quit attempts and quitting, often among
those resistant to do so. Sampling of medication, particularly
NRT, is easy to disseminate within any number of real-world
medical settings, reaching large numbers of smokers. The role of
alternative tobacco products to promote quitting is less clear.
There is strong need for large scale, randomized, but still
naturalistic studies of products, particularly e-cigarettes, which
may or may not promote quit attempts and cessation. Dr.
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